H.C. Wainwright Starts Faeth Therapeutics (FTH) at Buy
H.C. Wainwright analyst Patrick R. Trucchio initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $60.00.
The analyst commented: "Initiating coverage of Faeth Therapeutics with a Buy rating and a $60 price target. Our Buy rating reflects our conviction on Faeth's clinical-stage oncology pipeline centered on multi-node inhibition of the PI3K/AKT/mTOR (PAM) pathway. Founded in 2019, and acquired in February 2026 by Sensei Biotherapeutics in a transaction that included a concurrent $200 million private placement, the combined company is focused on PIKTOR, an all-oral combination of serabelisib—a selective inhibitor of PI3Kα—and sapanisertib—a dual inhibitor of mTORC1/2—being evaluated in multiple solid tumors including endometrial, breast, and ovarian cancers. We believe that the clinical data generated to-date position PIKTOR as a differentiated approach in a space that Celcuity (CELC; Buy; Ramakanth) has validated with its Phase 3 VIKTORIA-1 data using gedatolisib—an intravenously-delivered (IV) pan-PI3K/mTOR inhibitor—and which Eli Lilly (LLY; not rated) has underwritten at $2.5 billion through its January 2025 acquisition of Scorpion Therapeutics’ STX-478—a mutant-selective PI3Kα inhibitor. Ahead of the next value inflection points for Faeth, including topline Phase 2 data in endometrial cancer by year-end 2026 and initial Phase 1b breast cancer data in 2027, we assume coverage of FTH with a Buy rating and $60 price target."
For an analyst ratings summary and ratings history on Faeth Therapeutics click here. For more ratings news on Faeth Therapeutics click here.
Shares of Faeth Therapeutics closed at $17.82 yesterday.